Brenntag SE Ticker Confused with Wrong Company News: BNR Stands for Burning Rock Biotech
This article was created with the help of artificial intelligence.
Key Takeaways
- The ticker symbol BNR on the NASDAQ belongs to Burning Rock Biotech Limited from Guangzhou, China, not to Brenntag SE.
- Burning Rock reported revenue of $15.649 million in the first quarter of 2026 on June 9, 2026, a decline of 14.67 percent compared to the prior-year period ($18.340 million).
- Loss per share remained unchanged at $0.20 compared to the first quarter of 2025.
- Brenntag SE, the German chemical distributor, is traded on the Frankfurt Stock Exchange in the DAX and has no connection to the BNR ticker.
- Burning Rock Biotech focuses on next-generation sequencing technology (NGS) for precision oncology and molecular cancer diagnostics.
The ticker symbol BNR on the NASDAQ belongs to Burning Rock Biotech Limited, a Chinese biotech company based in Guangzhou, not the German chemical distributor Brenntag SE. Current news regarding BNR refers exclusively to the US-listed company Burning Rock.
Burning Rock Biotech: Quarterly Results from June 9, 2026
Burning Rock Biotech Limited reported financial results for the first quarter of 2026 on June 9, 2026. The company achieved revenue of $15.649 million, representing a decline of 14.67 percent compared to the prior-year period. In the first quarter of 2025, Burning Rock had generated $18.340 million.
The loss per share remained unchanged at $0.20 compared to the prior-year quarter. Burning Rock focuses on the application of next-generation sequencing technology (NGS) in the field of precision oncology – a method for analyzing tumor DNA designed to enable personalized cancer therapies.
Brenntag SE: No Connection to Ticker BNR
Brenntag SE, the world's leading chemical distributor headquartered in Essen, is not listed under the ticker symbol BNR. The company is traded on the Frankfurt Stock Exchange in the DAX. An assignment of the BNR ticker to Brenntag is based on a confusion of stock exchange symbols.
The business segments of both companies differ fundamentally: while Brenntag operates as a distributor for industrial and specialty chemicals, Burning Rock focuses on molecular diagnostic tests and genomic sequencing for cancer treatment.
Market Environment for Burning Rock Biotech
Benzinga reported on June 12, 2026, on several stocks that lost value following previous price increases. Burning Rock was mentioned in this context. Specific price data or percentages were not provided in the reporting.
The Chinese biotech company operates in a highly competitive market for molecular diagnostics. NGS-based tests are increasingly being used in personalized medicine but are also under cost pressure due to regulatory requirements and reimbursement policies.